NetTargets Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
21
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
10
NetTargets General Information
Description
Developer of a drug discovery platform designed to discover novel drug targets. The company's platform uses systems biology and machine learning to compile chemical, biological, experimental, and clinical data, enabling pharmaceutical companies to discover new drugs more efficiently and effectively.
Contact Information
Website
www.net-targets.comCorporate Office
- 104 Daeduk University Business Incubator
- 68 Gajeongbuk-ro Yuseong-gu
- Daejeon, 34141
- South Korea
Corporate Office
- 104 Daeduk University Business Incubator
- 68 Gajeongbuk-ro Yuseong-gu
- Daejeon, 34141
- South Korea
NetTargets Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Accelerator/Incubator | 01-Jan-2023 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series A) | 27-Jun-2021 | Completed | Generating Revenue | |||
| 2. Seed Round | 15-Apr-2020 | $501.82 | Completed | Startup | ||
| 1. Accelerator/Incubator | 01-Oct-2019 | $501.82 | $501.82 | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
NetTargets Patents
NetTargets Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025249945-A1 | Single-cell gene expression time-series simulation and ode-based immune target prediction method | Pending | 30-May-2024 | ||
| WO-2024219864-A1 | Novel compound exhibiting setdb1 inhibitory activity, and use thereof | Inactive | 18-Apr-2023 |
NetTargets Signals
NetTargets Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| BS Investment Partners | Venture Capital | Minority | ||
| CKD Venture Capital | Corporate Venture Capital | Minority | ||
| DA Value Investment | Growth/Expansion | Minority | ||
| Friend Investment Partners (Seoul) | Venture Capital | Minority | ||
| GU Equity Partners (Korea) | Venture Capital | Minority |
NetTargets FAQs
-
When was NetTargets founded?
NetTargets was founded in 2019.
-
Where is NetTargets headquartered?
NetTargets is headquartered in Daejeon, South Korea.
-
What is the size of NetTargets?
NetTargets has 21 total employees.
-
What industry is NetTargets in?
NetTargets’s primary industry is Discovery Tools (Healthcare).
-
Is NetTargets a private or public company?
NetTargets is a Private company.
-
What is NetTargets’s current revenue?
The current revenue for NetTargets is .
-
How much funding has NetTargets raised over time?
NetTargets has raised $7.13M.
-
Who are NetTargets’s investors?
BS Investment Partners, CKD Venture Capital, DA Value Investment, Friend Investment Partners (Seoul), and GU Equity Partners (Korea) are 5 of 10 investors who have invested in NetTargets.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process